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There is increasing evidence for widespread occurrences
of infection with Epidermodysplasia verruciformis-
related human papillomaviruses, both in the general
population and in immunosuppressed patients. In order
to test for the prevalence of antibodies directed against
the native L1 epitopes exposed on the surface of the
virions, we have established an IgG-specific enzyme-
linked immunosorbent assay with L1 virus-like particles
of the Epidermodysplasia verruciformis-specific human
papillomavirus 8 as antigen to screen 567 representative
serum samples from the general population and
immunosuppressed/dermatologic patients. Among
healthy European donors (n J 210), 7.6% were found
Clinically apparent infections of the skin by humanpapillomaviruses (HPV) result in a variety of hyperplas-tic, papillomatous, or verrucous tumors of thesquamous epithelium (Shah and Howley, 1996;Wieland and Pfister, 1997). Almost all lesions induced
by the cutaneous HPV types in immunocompetent individuals are
benign and eventually regress due to a complex, poorly understood
response of the immune system (Tindle and Frazer, 1994).
A striking exception to this rule is the rare skin disease
Epidermodysplasia verruciformis (EV). EV patients suffer from
multiple, life-long persisting flat warts and macular skin lesions,
frequently disseminated all over the body. EV tumors develop after
infection by several HPV types that are specific for induction of
EV lesions (Orth, 1987; Fuchs and Pfister, 1996). Within 20–30 y
from onset of the disease, the primarily benign skin lesions undergo
malignant conversion in 30%–60% of the patients, mostly on sun-
exposed areas of the body (Tanigaki et al, 1986; Orth, 1987).
Interestingly, out of over 20 EV-associated HPV types, HPV5 and
HPV8 can be found in more than 90% of the EV cancers (Pfister,
1992). There are data arguing for some undefined genetic defect
of the cell-mediated immunity, probably responsible for the
susceptibility of EV patients to infections by specific HPV types
(Jablonska and Majewski, 1994).
Manuscript received October 18, 1997; revised June 19, 1998; accepted for
publication June 19, 1998.
Reprint requests to: Dr. Herbert Pfister, Institut fu¨r Virologie der Universita¨t
zu Ko¨ln, Fu¨rst-Pu¨ckler-Str. 56, D-50935 Ko¨ln, Germany.
Abbreviations: EV, Epidermodysplasia verruciformis; PBST, PBS/
0.05%Tween20; RTR, renal transplant recipient; VLP, virus-like particle.
0022-202X/98/$10.50 · Copyright © 1998 by The Society for Investigative Dermatology, Inc.
696
to be seropositive. In a group of renal transplant
recipients (n J 185) the antibody prevalence was
elevated to 21.1%, irrespective of the presence or
absence of skin cancer. High positivity rates could be
detected among (i) immunocompetent patients with
nonmelanoma skin tumors (45.6%, n J 79) and (ii)
Psoralene/UVA treated psoriasis patients (42.9%,
n J 42). In contrast, anti-human papillomavirus 8-
virus-like particle antibodies were found in only 6.8%
of Hodgkin lymphoma patients (n J 44). Key words:
psoriasis/renal transplant recipients/seroepidemiology/UV
light. J Invest Dermatol 111:696–701, 1998
The EV-HPV were originally believed to infect the EV patients
only; however, recent studies clearly demonstrated that DNA of
EV viruses may also occur in normal human skin, as well as in
premalignant and malignant skin tumors in patients without EV
(Pfister and ter Schegget, 1997). Using a nested polymerase chain
reaction technique, sequences of EV-specific HPV could be detected
in up to 80% of squamous cell carcinomas of immunosuppressed
renal transplant recipients (RTR) (de Jong-Tieben et al, 1995).
Prevalences of 62% and 41% have also been reported for squamous
cell carcinomas and basal cell carcinomas of immunocompetent
patients, respectively (Pfister and ter Schegget, 1997). An intriguing
hypothesis concerning a source of the widespread skin infections
by EV-specific HPV types has recently been proposed by Boxman
et al (1997), who detected subclinically persisting EV-HPV-DNA in
plucked hairs of 45% of healthy donors and of all RTR examined.
A high prevalence of EV-HPV infections was also indicated by
a seroepidemiologic study using western blots with bacterially
expressed major capsid protein L1 of HPV8 (Steger et al, 1990),
which detected specific anti-L1 IgG antibodies in 20% of the
general population and in 40%, 73%, and 48% of patients with
basaliomas, squamous cell carcinomas, and Hodgkin’s disease,
respectively. The antibody prevalence in RTR was 50% (Bouwes
Bavinck et al, 1993). Antigens in the form of denatured proteins
consist predominantly of linear epitopes and may therefore fail to
detect antibodies specific for conformational epitopes on the surface
of the virions. On the other hand, linear L1 proteins contain
conserved cross-reactive regions that may be recognized by a broad
range of type-common antibodies.
In the meantime, artificially synthesized, empty papillomavirus
capsids [virus-like particles (VLP)] became available and were
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successfully employed as antigen in serologic studies (Schiller and
Roden, 1995). VLP can be generated by self-assembly of L1 or L1
and L2 proteins overexpressed in vaccinia virus-, baculovirus-,
semliki forest virus-, or yeast-systems, and display structural features
very closely resembling those of the native virions (Hagensee
et al, 1994).
Serum antibodies against HPV-VLP turned out to be a useful
marker of HPV infection with 58%–89% of individuals with clinical
lesions or HPV DNA being seropositive compared with 6%–19%
of individuals without HPV DNA or disease history (Carter et al,
1994, 1995; Kirnbauer et al, 1994; Heim et al, 1995). Prolonged
exposure to viral antigen turned out to be a primary determinant
of a detectable antibody response (Wideroff et al, 1995). Unlike DNA-
based assays, VLP-enzyme-linked immunosorbent assay (ELISA) are
able to detect past infections. Antibodies were shown to persist
after loss of HPV DNA (Wikstrom et al, 1995). Seroreactivity to
HPV16 VLP in currently HPV DNA negative women strongly
correlated with their number of sexual partners and proved to be
superior to HPV DNA prevalence as a marker for cervical cancer
risk in high-risk populations (Nonnenmacher et al, 1996; Wideroff
et al, 1996). In contrast to HPV DNA detection, serologic analysis
does not depend on a precise sampling of the tissue, which obviously
is a particular problem in epidemiologic studies of skin infections.
Because HPV8 is one of the candidates to play an important
role in cutaneous carcinogenesis and represents one of the best
studied EV-HPV, we were interested in the actual seroprevalence
as defined by a VLP-ELISA for this specific type. We report here
on the establishment of an ELISA with HPV8-VLP as antigen and
present the results of screening for specific IgG antibodies in the
general population and in immunocompetent patients with skin
tumors. Patients with Hodgkin lymphoma served as a control group
with another type of malignant disease, and PUVA-treated psoriasis
patients represented UV-exposed individuals with a benign hyperprol-
iferative skin disorder. Immunosuppressed RTR were included due
to an increased risk of skin cancer (Hoxtell et al, 1977; Bouwes
Bavinck and Berkhout, 1997).
MATERIALS AND METHODS
Construction of the recombinant baculovirus expressing HPV8 L1
protein To construct recombinant baculoviruses expressing the L1 protein
of HPV8, the L1 open reading frame was amplified using the primers 59-
TAGTAGGGATCCGC-CACCATGGCAGTGTGGCAA-39 and 59-ATGA-
TGAAGCTTCCTTGAATACTGTGT-39, which correspond to HPV8
sequences between nt. 5851–5865 and 7445–7431 (Fuchs et al, 1986) and
contain recognition sites for BamHI and HindIII engineered into their 59
parts, respectively. The cloned genomic DNA of HPV8 was used as a
polymerase chain reaction template. The amplified L1 gene was cloned into
baculovirus transfer vector (pBlueBacIII, Invitrogen, Leek, The Netherlands)
via BamHI and HindIII sites followed by recombination with linearized
wild-type AcMNPV baculovirus DNA. Resulting recombinant baculoviruses
were plaque purified in the semi-solid agarose medium containing 5-bromo-
4-chloro-3-indolyl-β-D-galactoside (X-gal). Expression of the capsid proteins
by recombinant baculoviruses was determined by immunofluorescence,
coomassie blue staining, and immunoblot as described in detail by Ghim
et al (1996).
Purification of virus-like particles High Five-insect cells (Trichoplusia
ni 5B1–4, Invitrogen) were cultivated in Express Five-serum-free medium
(Gibco, Karlsruhe, Germany) at 27°C. Confluent cultures were collected
and infected with baculo-HPV8 L1-virus stock. Seventy-two hour post-
infection cells were harvested, the pellet was resuspended in a total volume
of 5 ml phosphate-buffered saline (PBS), 1 mM phenylmethylsulfonyl
fluoride, 10 µg Aprotinin per ml, and sonicated on ice for 3 3 10 s at
40 W. The crude extract was loaded on top of a 40% (wt/vol) sucrose/
PBS-cushion in SW28 tubes and centrifuged at 113,000 3 g for 2.5 h at
4°C. The pellet was resuspended in 29% (wt/vol) CsCl/PBS and centrifuged
to equilibrium at 183,000 3 g in a 50TI rotor for 60 h. Fractions were
collected from the bottom of the tubes and dialyzed against PBS three
times for 1 h at 4°C. Fractions were tested for immunoreactivity in the
ELISA with an HPV8 L1-positive and a negative serum. Protein concentration
of VLP preparations was determined by BCA Protein-Assay (Pierce, Oud
Beijerland, The Netherlands).
Electron microscopy Diluted VLP preparations were immobilized on
300 mesh Formvar/carbon-coated grids and negatively stained with 1%
uranyl acetate. VLP were examined with a Zeiss EM9 S2 transmission
electron microscope at the magnification of 330,000.
Establishment of the VLP-ELISA The ELISA procedure was established
by using the following antigens: a bacterially expressed denatured HPV8 L1
protein (Steger et al, 1990), denatured and assembled VLP. A guinea pig
anti-serum directed against denatured L1 protein and sera of two EV patients
known to be HPV8 DNA positive served for antigen detection. Five sera
from 0.5 to 1.5 y old children were initially used as supposedly
negative controls.
PBS/0.05% Tween 20 (PBST) was chosen as a blocking solution because
of the best signal-to-background ratio. Sera dilutions, the washing solution,
and the washing procedure were optimized. By these means the saturating
amount of antigen for each well was determined.
VLP-ELISA Nunc Maxisorp-ELISA plates were coated with 100 ng of
the VLP preparations in 50 µl PBS for 1 h at 37°C. After three washings
with PBS the wells were blocked by incubation with 200 µl PBST for 1 h
at 37°C. Patients’ sera were diluted 1:50 in PBST and incubated in duplicate
wells for 1 h at room temperature. After five washes with PBST the
peroxidase-conjugated goat anti-human IgG (Fcγ fragment-specific, Affipure,
Dianova, Hamburg, Germany), diluted 1:20,000 in PBST was added to the
wells for 1 h at room temperature. Following five washes with PBST,
100 µl of the peroxidase substrate diammonium 2,29-azino-bis(3-ethylbenz-
thiazoline-6-sulfonate) (ABTS, Boehringer, Mannheim, Germany) was added
and incubated for 45 min at room temperature. The optical densities were
determined in the ELISA reader at 405 nm.
For each serum sample the OD value of an antigen-free well was
subtracted from the mean value of duplicate wells coated with VLP. A
positive serum with an OD of 1.0 was included on each plate. The
definition of the cut-off value for HPV8 and HPV16 antigen was based on
the distribution of the OD values of 210 or 149 sera from the general
population, excluding the outliers (Heim et al, 1995). The individual values
exceeding the mean 1 3 SD were excluded, and the remaining readings
were averaged again until no further values exceeded the recalculated
mean 1 3 SD.
Western blot analysis Sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis was carried out under reducing conditions in 10% polyacrylamid
slab gels using the discontinuous buffer system of Laemmli (1970). VLP
were denatured by heating at 95°C for 10 min in sodium dodecyl sulfate-
sample buffer. Following electrophoresis, proteins were stained with Coomassie
brilliant blue R250. For the western blot, proteins were transferred to
nitrocellulose membrane for 2 h by the semi-dry blotting procedure (Kyhse-
Andersen, 1984). The nitrocellulose membrane was stained for protein with
Ponceau S and destained completely in PBST. Unspecific binding sites on
nitrocellulose membrane were saturated with 1% bovine serum albumin and
1% dry milk in PBST for 1 h at room temperature. Guinea pig anti-
HPV8 L1 anti-serum (Steger et al, 1988) was diluted 1:800 in blocking
solution. Specific antigen-antibody complexes were detected by rabbit anti-
guinea pig IgG peroxidase conjugate (1:3000) using the ECL-system
(Amersham, Freiburg, Germany) for detection.
Studied collectives Sera from five different patient groups were enrolled
in this study. As a control group representing the general population, 210
sera of healthy blood donors, collected in the University Hospital of
Cologne, were tested. Sera of five EV patients were provided by the
Department of Dermatology, Warsaw; two were obtained from G. Fierlbeck,
Dermatologic University Hospital in Tu¨bingen.
The group of RTR consisted of 127 patients from the Transplantation
Center Leiden, the Netherlands (Bouwes Bavinck et al, 1991, 1993). All
patients were immunosuppressed for about 13 y. Another 58 sera from
RTR were provided by the Department of Dermatology, University of
Edinburgh, Scotland. Sera of 44 Morbus Hodgkin patients and 42 psoriasis
patients subjected to treatment with psoralene and UVA light (PUVA
therapy) originated from the University Hospital Hamburg-Eppendorf.
Sera of 79 patients with skin tumors (basaliomas, spinaliomas, and/or
M. Bowen-lesions) were collected at the Dermatologic University Hospital
in Kiel.
RESULTS
Characterization of HPV8 VLP The dialyzed fractions from
the CsCl gradients were initially analyzed by reducing sodium
dodecyl sulfate-polyacrylamide gel electrophoresis to identify those
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Figure 1. Analysis of HPV8-LI VLP. (A) Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis analysis of purified HPV8 L1 VLP. M,
molecular weight marker 10 kDa ladder; 1, Coomassie blue stained gel; 2,
western blot with guinea pig anti-HPV8 L1 anti-serum. (B) Electron
micrograph of negatively stained HPV8 L1 VLP. Scale bar: 100 nm.
containing the L1 protein. The central fractions of the gradients
showed a prominent 60 kDa protein band, corresponding to the
approximate molecular weight expected for the HPV8 L1 polypeptide.
The identity of this protein as L1 was verified by immunoblot with
anti-HPV8 L1 guinea pig anti-serum (Fig 1A). Besides the 60 kDa
L1 protein, a weak band of about 52 kDa was detectable in western
blots. As previously reported (Pfister et al, 1977), this fraction most
likely represents a degradation product of the full-length L1 protein.
Analysis by transmission electron microscopy revealed spherical
particles with a diameter of about 60 nm that seemed to be
composed of capsomers; however, it also contained smaller, irregular
structures (Fig 1B). The CsCl fractions with an average buoyant
density of 1.3 g per ml contained the highest concentrations of L1
protein and virus-like particles and corresponded to visible bands in
the gradients.
VLP-containing fractions were also strongly positive in the ELISA
test using an EV patient’s serum (Fierlbeck et al, 1989). The
hyperimmune guinea pig anti-serum to bacterially expressed HPV8-
L1 protein (Steger et al, 1988) reacted both with assembled and
with disrupted VLP (5% sodium dodecyl sulfate, 20 mM dithiothreitol,
10 min 95°C); however, the denatured capsids were not detected
by the EV serum (data not shown).
Prevalence of anti-HPV8 VLP antibodies in different
collectives The results of the serologic assays are summarized in
Fig 2 and Table I. As a control group representing the general
population, 210 sera of healthy blood donors were tested. The cut-
off value for HPV8-VLP ELISA was determined to be 0.304. The
OD values of serologic reactions in the general population revealed
a normal distribution. In the control group 16 of 210 sera reacted
with VLP. In contrast, four of seven sera from patients with EV
tested positive. Three of these patients were known to be infected
with HPV8 by DNA analysis and two of them were seropositive
(Fierlbeck et al, 1989; S. Jablonska, Department of Dermatology,
Warsaw, Poland, personal communication).
Apart from EV, patients with nonmelanoma skin tumors had the
highest prevalence of antibodies (45.6%) among the different groups.
Ten of 14 spinalioma patients and eight of 12 Morbus Bowen
patients had IgG antibodies reactive with HPV8 VLP, whereas only
19 of 54 patients with basal cell carcinomas were seropositive.
Of 44 sera of Hodgkin-lymphoma patients, three were positive
for anti-HPV8 VLP antibodies, which corresponds to the seropreval-
ence in the general population.
Figure 2. Distribution of frequency of sera from different groups
reacting with HPV8 L1 VLP at different levels as measured by
extinction at 405 nm. The cut-off of 0.304 is indicated by arrows.
Psoriasis patients treated with Psoralene/UVA showed a surprisingly
high seropositivity; 43 per cent of the sera contained antibodies to
the HPV8 major capsid protein.
In the immunosuppressed RTR, 39 of 185 sera contained IgG
antibodies to HPV8 VLP (21.1%). This prevalence appears to be
significantly elevated when compared with the general population
(p , 0.001). A similar seropositivity was observed for patients with
spinaliomas (26.7%) and basal cell carcinomas (22.2%), respectively.
Both in the control group and in RTR a significant fluctuation
in seroprevalence for different age groups of patients was not
observed (Table II). There was no significant correlation between
seropositivity and sex seen in the control group, RTR, and skin
tumor patients (data not shown).
Positive cases from the general population showed moderate
seroreactivity, with OD values not exceeding 0.65. In contrast 23%
of the skin tumor patients revealed stronger ELISA reactions with
OD values in the range of 0.65–2.15.
A total of 391 sera was tested in parallel for ELISA reactivity
against HPV8 and HPV16 VLP (Fig 3). Both anti-HPV8 and anti-
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Table I. Serum ELISA reactivity to HPV8 L1-VLP of
control and patient groups
HPV8 Pos. 95%
Collective n pos. (%) conf. interval
Skin tumor patients 79 36 45.6 34.6; 56.6
SCCa 14 10 71.4 47.8; 95.1
M. Bowen 21 8 66.7 40.0; 93.3
BCCa 54 19 35.2 22.4; 47.9
General population 210 16 7.6 4.0; 11.2
Controls
Hodgkin lymphoma patients 44 3 6.8 0.0; 14.3
Psoriasis patients (PUVA-treated) 42 18 42.9 27.9; 57.8
Immunosuppressed population 185 39 21.1 15.2; 27.0
RTR from Edinburgh 58 10 17.2 7.5; 27.0
RTR from Leiden 127 29 22.8 15.5; 30.1
without skin cancer 89 20 22.5 13.8; 31.1
with skin cancer 28 9 23.7 10.2; 37.2
SCCa 30 8 26.7 10.8; 42.5
BCCa 18 4 22.2 3.0; 41.4
aSCC, squamous cell carcinoma; BCC, basal cell carcinoma. Values of patients
with SCC and BCC were counted to both groups.
Table II. Age distribution of patients and seroprevalences to
HPV8-VLP in three different collectives
General Skin tumor
population RTR patients
Age group (y) n % pos. n % pos. n % pos.
0–10 21 9.5 0 – 0 –
10–30 76 5.3 8 25.0 0 –
30–50 66 10.6 73 20.5 5 0
.50 47 6.4 46 26.1 74 48.6
Total 210 7.6 127 22.8 79 45.6
HPV16 antibodies were detected in 14 sera, 81 sera showed anti-
HPV8 antibodies only, and 22 sera showed anti-HPV16 antibodies
only. The prevalence of anti-HPV16 antibodies was 10.3% in the
general population, 16.5% in skin cancer patients, 4.8% in RTR,
and 4.8% in PUVA-treated psoriasis patients.
DISCUSSION
The development of recombinant VLP offers for the first time a
reliable, generally available source of papillomaviral conformational
capsid antigens. As proven by several reports on genital HPV
infections, VLP may be especially useful for seroepidemiologic
studies, which so far suffered from the lack of suitable reagents.
The VLP-based ELISA represents a specific method for initial
detection and subsequent follow-up of the humoral response to
HPV virions (Schiller and Roden, 1995). In contrast to genital
infections, scant attention has been focused on HPV infections of
the skin. Because of emerging evidence for a high prevalence of
EV-associated viruses in both normal and diseased human skin
(Pfister and ter Schegget, 1997), we focused on the prevalence of
antibodies against the major surface antigen of HPV8.
Due to the small number of available EV patients where HPV8
infection has been proven by detection of viral DNA, it is difficult
to validate to what degree antibodies against HPV8 VLP reflect
current or past HPV8 infection. Based on our limited analysis of
seven EV patients, there is some indication that sensitivity (two
seropositive/three DNA positive) and seropositivity of individuals at
risk is similar to that observed in extensive studies with genital
HPV (Kirnbauer et al, 1994; Carter et al, 1995). The significance
of HPV8 DNA negative test results in random samples of EV
patients is obviously limited in view of the large target organ skin.
Figure 3. Correlation of serum ELISA IgG reactivity to HPV8 and
HPV16 L1 VLP. Sera from (A) general population (n 5 145); (B)
psoralene/UVA-treated psoriasis patients (n 5 42); (C) RTR (n 5 125);
(D) skin tumor patients (n 5 79). The cut-off for the HPV8 VLP-ELISA
(0.304) is indicated by vertical lines, and the cut-off for the HPV16 VLP-
ELISA (0.348) by horizontal lines.
Table III. Detection of anti-HPV8-L1 antibodies by western
blota and VLP-ELISA in 124 sera of RTR
Group Western blot VLP-ELISA Number of sera
A 1 1 12
B 1 – 50
C – 1 16
D – – 46
aData from Bouwes Bavinck et al. (1993).
Our results reveal a significantly higher prevalence of anti-HPV8
antibodies in individuals with skin cancer in comparison with the
non-selected general population. The seroprevalence was also higher
in psoriasis patients and RTR. A parallel testing of these sera in an
HPV16-VLP ELISA showed no obvious cross-reactivity between
HPV8 and HPV16 and demonstrated no elevated reactivity of the
patients sera with HPV16 antigen in comparison with the general
population. For RTR and skin cancer patients HPV8 seroprevalences
generally confirm earlier data based on western blot analysis (Steger
et al, 1990; Bouwes Bavinck et al, 1993); however, some of the
observed prevalences differ considerably. Whereas the immunocompe-
tent skin cancer patients showed roughly the same, high antibody
prevalence in both assays, the overall positivity of immunocompetent
(general population) and immunocompromised (RTR, Hodgkin
patients) individuals was only about one-third of the previous
immunoblot results. The difference in reactivity of sera in western
blot and the VLP-ELISA became particularly obvious when
comparing individual patients. With 124 RTR, we consistently
found positive or negative results for 58 sera (Table III, groups A
and D). Fifty western blot-positive sera (group B) turned out to
be negative in the ELISA-test and 16 sera (group C) negative in
the immunoblot reacted in the VLP-ELISA. These discrepancies
can be explained best by different specificities of each method that
detect different sets of antibodies.
The large number of western blot-positive/ELISA-negative sera
may reflect the fact that linear epitopes presented in the immunoblot
are able to react with antibodies against the subgenus of EV-
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associated HPV and not against HPV8 alone (Steger et al, 1990;
Bouwes Bavinck et al, 1993). In contrast, the VLP ELISA appears
more type restricted. Only a partial cross-reactivity of sera was
observed in a VLP-ELISA with the most closely related genital
HPV types 6 and 11 (Heim et al, 1995); however, VLP preparations
do not only contain perfectly assembled particles and it is therefore
not possible to exclude limited cross-reactivity in the HPV8-ELISA
with some EV-associated viruses sharing the same or similar L1
surface epitopes.
The existence of VLP-ELISA-positive/western blot-negative sera
may be explained by a preferential immune response of these
individuals against conformational surface epitopes specifically detected
by the VLP-ELISA.
In spite of the fact that the immunoblot- and VLP-ELISA-tests
obviously detect different repertoires of antibodies, both these
methods congruently point to a widespread occurrence of EV-
specific HPV and to a very high prevalence in skin cancer patients.
It is remarkable that the more type-specific HPV8-VLP ELISA still
detected antibodies in 7.6% of the sera from the general population.
The difference in prevalence between skin cancer patients and
controls appears even accentuated with the HPV8-VLP ELISA. In
line with this seroepidemiologic association between HPV8 and
cutaneous cancer, HPV8-DNA could be demonstrated in two of
34 squamous cell carcinomas and in one of 11 tested basal cell
carcinomas of the general population (Stark et al, 1994; Shamanin
et al, 1996); however, HPV8-DNA did not appear to be particularly
prevalent relative to other HPV types (Pfister and ter Schegget,
1997). It is apparent that the immune response in about half of
the skin cancer patients does not imply persistence of this HPV
type in the malignant tumor cells, which do not support the
expression of capsid proteins. The antibodies will rather reflect an
increased exposure to HPV8 antigens during previous or concomitant
viral replication in the nonmalignant epithelium.
Because of the low prevalence of anti-HPV8 antibodies in
Hodgkin-lymphoma patients, there seems to be no association
between an increased exposure to HPV8 antigens and malignancy
in general. The high prevalence of HPV8-specific antibodies in skin
cancer patients may be due to enhanced replication of HPV8 under
conditions that promote cutaneous malignancies. Sunlight is well
established as the most important risk factor for nonmelanoma skin
cancer and induces local immune suppression, which can in turn
facilitate viral replication (Vitaliano and Urbach, 1980; Kribke,
1994). This hypothesis is supported by the high seropositivity of
PUVA-treated psoriasis patients, who develop hyperkeratotic lesions
(UV keratoses) and skin cancer in a UV dose dependent manner
(van Praag et al, 1993; Studniberg and Weller, 1993). Recently, we
also observed a correlation between the presence of anti-HPV8 L1
antibodies and solar keratosis in fair skinned individuals living on
Saba (Bouwes Bavinck et al in preparation).1 The overall seropreval-
ence among 114 individuals tested on this tropical island was 46%;
37% in individuals with less than 37 solar keratoses (the median
number of solar keratoses in the group studied) and 54% in those
with 37 or more solar keratoses (unpublished data). The latter
observation forms additional support for the hypothesis that
seropositivity is promoted by UV exposure.
Another clearly recognized risk factor for skin cancer is an
acquired or iatrogenic systemic immune suppression (Hoxtell et al,
1977). Our analysis of immunocompromised RTR revealed a 3-
fold higher prevalence of HPV8-specific antibodies compared with
the general population; however, there was basically no difference
in the positivity rates between cancer and noncancer patients in
this group, and the seroprevalence in immunocompromised skin
cancer patients was considerably lower than that of the immuno-
competent ones. These seemingly conflicting data may be related
to the following specificities of the immunosuppressed patients: (i)
1Bouwes Bavinck JN, Stark S, Petridis AK, et al: The presence of antibodies
against virus-like particles of Epidermodysplasia verruciformis-associated human
papillomavirus type 8 is associated with actinic keratoses. Submitted.
the noncancer patients are at continuing high risk to finally develop
skin cancer and therefore do not represent an appropriate control
group in this regard; and (ii) the severe systemic immunosuppression
may at least partially hamper the humoral immune response.
Taken together, the prevalence of HPV8-specific antibodies
appears to be increased not only in skin cancer patients but also in
populations exposed to the two major risk factors in cutaneous
carcinogenesis: UV light and immunosuppression. It is not yet
known if activated replication fof HPV8 is an epiphenomenon or
if it plays a causal role in cancer development. It will be very
interesting to see whether other HPV types detectable in cutaneous
cancers follow a similar seroepidemiology. Carefully designed
epidemiologic studies are necessary to assess the significance of the
increased seroprevalence in HPV-related skin-specific oncogenesis.
They have to include detection and typing of HPV DNA in
plucked hairs and tumor specimens. It is furthermore essential to
analyze all of the factors potentially influencing the immune response
to the viral antigens (e.g., sex, age, skin type, sun exposure and/
or UV exposure, presence of other hyperproliferative skin disorders).
Recombinant baculovirus expressing HPV16 L1 was a gift of R. Kirnbauer, Vienna.
A part of the sera from RTR and healthy donors were provided by E.C. Benton,
Edinburgh and R. Grunenberg, Cologne. Sera of EV patients were a gift from S.
Jablonska, Warsaw. This work was supported by the German Ministry of Education,
Science, Research and Technology (Center for Molecular Medicine Cologne; 01
KS 952).
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